Phase I Trial of Concurrent Stereotactic Body Radiotherapy and Nelfinavir for Locally Advanced Borderline or Unresectable Pancreatic Adenocarcinoma

INTRODUCTION: The HIV protease inhibitor nelfinavir (NFV) displays notable radiosensitizing effects. There have been no studies evaluating combined stereotactic body radiotherapy (SBRT) and NFV for borderline/unresectable pancreatic cancer. The primary objective of this phase I trial (NCT01068327) w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Radiother Oncol
Autors principals: Lin, Chi, Verma, Vivek, Ly, Quan P., Lazenby, Audrey, Sasson, Aaron, Schwarz, James K., Meza, Jane L., Are, Chandrakanth, Li, Sicong, Wang, Shuo, Hahn, Stephen M., Grem, Jean L.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6400311/
https://ncbi.nlm.nih.gov/pubmed/30825970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2018.11.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars